RRM2 protects against ferroptosis and is a tumor biomarker for liver cancer

• Published in: Cancer cell international 2020-12, Vol.20 (1), p.587-587, Article 587
• Main Authors: Yang, Yueyue, Lin, Jiafei, Guo, Susu, Xue, Xiangfei, Wang, Yikun, Qiu, Shiyu, Cui, Jiangtao, Ma, Lifang, Zhang, Xiao, Wang, Jiayi
• Format: Article
• Language: English
• Subjects: Alanine; Alanine transaminase; Alkaline phosphatase; Antibodies; Apoptosis; Aspartate aminotransferase; Bilirubin; Bioinformatics; Biomarkers; Carcinoembryonic antigen; Cell death; Cell division; Cell viability; Diagnosis; Enzyme-linked immunosorbent assay; Erastin; Ferroptosis; Flow cytometry; Glutathione; GSS; Hepatitis; Hepatocytes; Hospitals; Immunoblotting; Immunofluorescence; Immunoprecipitation; Liver cancer; Metabolites; Patients; Phosphorylation; Plasmids; Polymerase chain reaction; Primary Research; Proteasome; Proteasomes; Protein expression; Proteins; Threonine; α-Fetoprotein; γ-Glutamyltransferase
• ISSN: 1475-2867; 1475-2867
• DOI: 10.1186/s12935-020-01689-8

Ferroptosis is the process of cell death triggered by lipid peroxides, and inhibition of glutathione (GSH) synthesis leads to ferroptosis. Liver cancer progression is closely linked to ferroptosis suppression. However, the mechanism by which inhibition of GSH synthesis suppresses potential ferroptosis of liver cancer cells and whether ferroptosis-related liver cancer biomarkers have a promising diagnostic value remain unknown. Ribonucleotide reductase regulatory subunit M2 (RRM2) levels were measured using an enzyme linked immunosorbent assay (ELISA), quantitative RT-PCR (qPCR), immunoblotting (IB) and immunochemistry (IHC). Cell viability and cell death were measured by a CellTiter-Glo luminescent cell viability assay and staining with SYTOX Green followed by flow cytometry, respectively. Metabolites were measured using the indicated kits. The Interaction between glutathione synthetase (GSS) and RRM2 was measured using immunofluorescence (IF), co-immunoprecipitation (co-IP) and the proximal ligation assay (PLA). The diagnostic value was analyzed using the area under the receiver operating characteristic curve (AUC-ROC). Bioinformatics analysis was performed using the indicated database. RRM2 showed specifically elevated levels in liver cancer and inhibited ferroptosis by stimulating GSH synthesis via GSS. Mechanistically, phosphorylation of RRM2 at the Threonine 33 residue (T33) was maintained at normal levels to block the RRM2-GSS interaction and therefore protected RRM2 and GSS from further proteasome degradation. However, under ferroptotic stress, RRM2 was dephosphorylated at T33, thus the RRM2-GSS interaction was promoted. This resulted in the translocation of RRM2 and GSS to the proteasome for simultaneous degradation. Clinically, serum RRM2 was significantly associated with serum alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma glutamyl transpeptidase (γ-GT), albumin (ALB) and total bilirubin. The AUC-ROC for the combination of RRM2 with AFP was 0.947, with a sensitivity of 88.7% and a specificity of 97.0%, which indicates better diagnostic performance compared to either RRM2 or AFP alone. RRM2 exerts an anti-ferroptotic role in liver cancer cells by sustaining GSH synthesis. Serum RRM2 will be useful as a biomarker to evaluate the degree to which ferroptosis is suppressed and improve diagnostic efficiency for liver cancer.